Topical minoxidil is the reference point every new hair compound is measured against. It is the only topical approved over the counter for pattern hair loss, it has decades of trial data behind it, and it is the comparator arm in study after study — including the one registered human trial of a 2-deoxy-D-ribose hydrogel.
The short version
- Minoxidil began as an oral antihypertensive; hair growth was observed as a side effect and the topical formulation followed.
- It is classed as a vasodilator. Its precise mechanism in hair is still not fully settled, which is worth knowing given how often it is described as understood.
- It is approved over the counter as a topical, most commonly at 2% and 5%.
- It is the active comparator in NCT07502976, the registered trial of a 2-deoxy-D-ribose hydrogel.
- Effects depend on continued use; the change fades over subsequent hair cycles after stopping.
Why is minoxidil the benchmark?
Three reasons, and only one of them is about performance.
First, it is approved, so it is ethically available as an active comparator rather than only placebo. Second, the endpoint conventions in this field — target area hair count, standardised photography, patient self-assessment — were largely established in minoxidil trials, so newer trials use them for comparability. Third, it is the thing most people have already tried, which makes it the reference readers actually hold in their heads.
That last one is why so many articles are framed as "X versus minoxidil". It is a framing about familiarity as much as evidence.
How does the evidence base compare across compounds?
Stage of evidence and mechanism class only. This is not a ranking by result: the trials used different designs, endpoints, durations and populations, so head-to-head efficacy comparison is not supported by the published data.
| Compound | Type | Mechanism class | Stage of evidence | Route |
|---|---|---|---|---|
| Minoxidil (topical) | Approved OTC drug | Vasodilator | Approved; decades of trial data | Topical |
| Clascoterone 5% | Investigational drug | Local androgen receptor inhibition | Phase 3 complete (NCT05910450, NCT05914805) | Topical |
| VDPHL01 | Investigational drug | Vasodilator, extended-release | Phase 2/3 reported (NCT06724614); two Phase 3 pending | Oral |
| PP405 | Investigational drug | Follicle stem-cell metabolism | Phase 2a complete (NCT06393452) | Topical |
| 2-deoxy-D-ribose | Cosmetic ingredient | Sugar studied for angiogenesis | Animal model published; one human RCT recruiting (NCT07502976), no results | Topical |
Interested in 2DDR?
Deoxylocks is a physician-formulated cosmetic scalp hydrogel with 5% 2-deoxy-D-ribose. Clear, odorless, once daily.
What is minoxidil's honest limitation profile?
It does not work for everyone, response varies, and it requires indefinite use to maintain any change. Local irritation is the common complaint, often attributed to the vehicle rather than the active ingredient. An initial increase in shedding is frequently reported early in use. None of that is hidden — it is in the labelling — but it tends to get compressed out of comparison articles.
What these results do not tell you
- A large evidence base is not a personal guarantee. A large evidence base establishes an average effect and a safety profile, not an individual outcome.
- Comparator status is not a ranking. Being the arm that new compounds are tested against reflects approval and availability, not superiority.
- Formulations differ. 2% and 5%, solution and foam, topical and oral are not interchangeable, and trial data does not transfer between them.
- The mechanism is not fully settled. Vasodilation is the standard description, but the full picture in hair follicles remains an open research question.
Where does 2-deoxy-D-ribose sit against this?
Further back, and in a different regulatory category. 2-deoxy-D-ribose (2DDR) is a naturally occurring pentose sugar. The work most often cited is a 2024 paper in Frontiers in Pharmacology from the University of Sheffield and COMSATS University, which applied it in a testosterone-driven mouse model and reported hair growth outcomes in that model similar to the minoxidil comparator used in the same study. That is an animal study, and the lead author described the work publicly as early stage.
One independent randomised controlled trial of a 2-deoxy-D-ribose hydrogel (NCT07502976) began recruiting in January 2026 at Kasr El Aini Hospital, with 60 participants estimated and primary completion listed for October 2026. No results have been posted. That trial is run by an academic hospital and is not a study of any commercial product.
So the honest summary is: an animal model, a mechanistic hypothesis about blood vessel formation, and one human trial that has not reported. Set against a completed Phase 3 programme, that is not a close comparison, and this article does not make one.
Deoxylocks is a physician-formulated cosmetic hydrogel containing 5% 2-deoxy-D-ribose. It is a scalp care product sold for cosmetic use. It is not a drug, it has not been through the trials described in this article, and nothing here was conducted on it. Anyone weighing the options in this article should speak with a clinician about their own situation.
Common questions
Why is minoxidil used as the comparator in the 2DDR trial?
Because it is the approved topical option, which makes it the standard active comparator for a topical scalp study. NCT07502976 lists a minoxidil 5% arm alongside the hydrogel arm. That trial is recruiting and has not reported.
Does an initial increase in shedding mean it is not working?
Early shedding is commonly reported when starting and is generally described as hair cycles resynchronising. It is a question for a clinician, not an article.
Is oral minoxidil the same as topical?
No. They are different routes with different exposure and different safety considerations. Oral formulations for hair loss are prescribed off-label in some settings, and a purpose-built extended-release version is in late-stage trials.
What happens if you stop?
The published position is that the effect depends on continued use and fades over subsequent hair cycles after stopping.
Last checked 15 August 2026.
Sources
Primary sources for the figures in this article. Registry records were checked on 15 August 2026.
- 2-Deoxy-D-ribose hydrogel vs minoxidil 5% (NCT07502976)
- Stimulation of hair regrowth in an animal model of androgenic alopecia using 2-deoxy-D-ribose
- University of Sheffield announcement
- SCALP 1 (NCT05910450)
- PP405 Phase 2a (NCT06393452)
- VDPHL01 Study 302 (NCT06724614)
Deoxylocks 5% 2DDR Scalp Hydrogel
A physician-formulated cosmetic hydrogel for nightly scalp care. Non-hormonal, clear and odorless, applied once daily to the scalp. Backed by a 90-day risk-free return policy.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
